Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Statement of Comprehensive Income
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The long-term activity ratios exhibit divergent trends across the analyzed period, characterized by a steady decline in fixed asset efficiency, a gradual improvement in overall asset utilization, and a significant structural shift in equity turnover beginning in early 2024.
- Net Fixed Asset Turnover
- A consistent downward trajectory is observed in net fixed asset turnover, decreasing from a peak of 7.90 in June 2022 to 6.31 by June 2026. This sustained decline indicates a diminishing capacity to generate revenue relative to the net investment in fixed assets, suggesting either an increase in capital expenditures that have not yet yielded proportional revenue growth or a general reduction in the productivity of fixed assets.
- Total Asset Turnover
- Total asset turnover demonstrates a gradual and steady improvement over the long term. After maintaining a range between 0.46 and 0.49 through 2023, the ratio began a positive ascent in mid-2024, eventually peaking at 0.56 in the first half of 2026. This trend suggests an increasing overall efficiency in utilizing the total asset base to drive sales, offsetting the decline seen in fixed asset productivity.
- Equity Turnover
- Equity turnover remained relatively stable between 1.41 and 1.55 from March 2022 through December 2023. A sharp inflection point occurred in March 2024, where the ratio jumped to 2.76, nearly doubling its previous baseline. While this elevated level of efficiency was maintained through 2024, a subsequent downward trend emerged starting in June 2025, with the ratio retreating to 2.20 by June 2026. This pattern indicates a major shift in the relationship between shareholder equity and revenue generation during the 2024 period, followed by a gradual normalization.
Net Fixed Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Property, plant and equipment | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Net fixed asset turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Property, plant and equipment
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio exhibits a consistent downward trend over the observed period, declining from 7.77 in March 2022 to 6.31 by June 2026. This contraction indicates a reduction in the efficiency with which the company generates revenue from its investment in long-term fixed assets.
- Revenue Performance
- Revenues remained relatively stable with moderate fluctuations, ranging from a low of 10,966 million US dollars in September 2023 to a peak of 12,973 million US dollars in June 2026. Although there was a general upward trajectory in the latter half of the period, the growth rate of revenues did not keep pace with the increase in the asset base.
- Fixed Asset Growth
- Property, plant, and equipment demonstrated a steady and uninterrupted increase throughout the entire timeframe. Asset values rose from 6,047 million US dollars in March 2022 to 7,791 million US dollars by June 2026, reflecting a sustained commitment to capital expenditure and infrastructure expansion.
- Asset Utilization Analysis
- The decline in the net fixed asset turnover ratio is primarily attributed to the disparity between the growth of the fixed asset base and the growth of top-line revenue. As the denominator (fixed assets) grew consistently while the numerator (revenues) grew more slowly or remained volatile, the resulting ratio decreased. This suggests that recent capital investments have not yet yielded a proportional increase in revenue generation, leading to lower asset productivity over the analyzed period.
Total Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Total asset turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio demonstrates a consistent upward trajectory over the analyzed period, rising from 0.46 in March 2022 to 0.56 by June 2026. This progression indicates a steady improvement in the efficiency with which the organization utilizes its total asset base to generate revenue.
- Revenue Trends
- Quarterly revenues remained relatively stable between March 2022 and December 2023, generally fluctuating between 10,966 million USD and 11,887 million USD. Starting in 2024, a gradual growth trend emerged, with revenues peaking at 12,973 million USD by June 2026. This represents a modest but steady increase in top-line performance toward the end of the period.
- Total Asset Dynamics
- The total asset base experienced an overall decline, decreasing from 103,034 million USD in March 2022 to 87,634 million USD in June 2026. Although a temporary increase occurred in early 2024, reaching 99,031 million USD, the long-term trend was characterized by a contraction of the balance sheet. The most significant reduction in assets occurred between September 2025 and March 2026.
- Efficiency Correlation
- The improvement in the total asset turnover ratio is the result of a dual effect: a contracting asset base paired with stable or increasing revenues. The ratio remained stagnant around 0.46 to 0.49 through 2022 and 2023, but accelerated upward starting in late 2024. The climb to 0.56 by mid-2026 suggests that the organization is generating more revenue per unit of asset, reflecting enhanced operational efficiency or a strategic lean toward a less asset-intensive business model.
Equity Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||
| Total BMS shareholders’ equity | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Equity turnover
= (RevenuesQ2 2026
+ RevenuesQ1 2026
+ RevenuesQ4 2025
+ RevenuesQ3 2025)
÷ Total BMS shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio experienced a significant structural shift starting in the first quarter of 2024, transitioning from a period of relative stability to a period of markedly higher ratios, followed by a gradual downward trend toward normalization.
- Revenue Performance
- Revenues remained relatively consistent throughout the analyzed period, with values generally fluctuating between 10,966 million USD and 12,973 million USD. While a slight upward trajectory is observable toward the end of the period, the overall stability of revenue indicates that the volatility in the equity turnover ratio was not driven by significant fluctuations in top-line performance.
- Shareholders' Equity Dynamics
- A substantial contraction in total shareholders' equity occurred between December 31, 2023, and March 31, 2024, with equity dropping from 29,430 million USD to 16,490 million USD. Following this sharp decline, a steady recovery trend is observed, with equity increasing progressively to 22,319 million USD by June 30, 2026.
- Equity Turnover Analysis
- From March 2022 through December 2023, the equity turnover ratio remained stable, oscillating within a narrow range of 1.41 to 1.55. The precipitous drop in shareholders' equity in early 2024 resulted in an immediate spike in the ratio to 2.76, peaking at 2.96 in December 2024. This suggests a significant increase in revenue generation per unit of equity, primarily due to a reduced equity base rather than an organic surge in sales. As the equity base began to expand again from 2025 onward, the turnover ratio gradually declined, reaching 2.20 by June 30, 2026.